$BIOLQ
BIOLASE, INC

2016 Q4 Form 10-K Financial Statement

#000156459017003972 Filed on March 10, 2017

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2016
Revenue $13.76M $13.23M $119.0K
YoY Change -5.23% 17.81% 0.0%
Cost Of Revenue $8.360M $7.620M $31.50M
YoY Change -7.01% -2.97% -4.23%
Gross Profit $5.400M $5.610M $20.31M
YoY Change -2.35% 70.0% 30.28%
Gross Profit Margin 39.24% 42.4% 17067.23%
Selling, General & Admin $7.220M $7.040M $27.47M
YoY Change 19.34% 2.03% -5.11%
% of Gross Profit 133.7% 125.49% 135.25%
Research & Development $2.300M $1.720M $7.800M
YoY Change 31.43% -2.05% 7.14%
% of Gross Profit 42.59% 30.66% 38.4%
Depreciation & Amortization $270.0K $290.0K $1.048M
YoY Change -6.9% 15.54% 19.09%
% of Gross Profit 5.0% 5.17% 5.16%
Operating Expenses $9.520M $8.760M $35.27M
YoY Change 22.05% 398.86% -2.65%
Operating Profit -$4.120M -$3.150M -$14.96M
YoY Change 81.5% -304.02% -24.88%
Interest Expense -$280.0K $40.00K -$260.0K
YoY Change 115.38% 90.48% -451.35%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$4.390M -$3.106M -$15.22M
YoY Change 82.16% -41.39% -24.28%
Income Tax $30.00K $40.00K $150.0K
% Of Pretax Income
Net Earnings -$4.430M -$3.146M -$15.37M
YoY Change 80.08% -41.12% -24.2%
Net Earnings / Revenue -32.19% -23.78% -12916.81%
Basic Earnings Per Share -$0.07
Diluted Earnings Per Share -$327.7K -$0.07 -$1.267M
COMMON SHARES
Basic Shares Outstanding 67.57M 58.55M
Diluted Shares Outstanding 58.55M

Balance Sheet

Concept 2016 Q4 2016 Q3 2016
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.920M $12.65M $8.920M
YoY Change -23.76% -16.72% -23.76%
Cash & Equivalents $9.175M $12.65M $8.920M
Short-Term Investments
Other Short-Term Assets $1.760M $1.150M $1.760M
YoY Change 10.69% -33.53% 10.69%
Inventory $13.52M $13.54M $13.52M
Prepaid Expenses
Receivables $9.784M $9.940M $9.700M
Other Receivables $23.00K $0.00 $80.00K
Total Short-Term Assets $33.99M $37.28M $33.99M
YoY Change -2.34% -7.45% -2.33%
LONG-TERM ASSETS
Property, Plant & Equipment $4.478M $3.860M $4.480M
YoY Change 20.15% 23.72% 20.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $550.0K $550.0K $550.0K
YoY Change -26.37% -27.63% -26.67%
Total Long-Term Assets $7.953M $7.340M $7.950M
YoY Change 6.74% 6.84% 6.71%
TOTAL ASSETS
Total Short-Term Assets $33.99M $37.28M $33.99M
Total Long-Term Assets $7.953M $7.340M $7.950M
Total Assets $41.94M $44.62M $41.94M
YoY Change -0.74% -5.37% -0.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.130M $7.880M $9.130M
YoY Change 53.19% -15.36% 53.19%
Accrued Expenses $4.770M $4.580M $4.770M
YoY Change -0.63% -11.41% -0.63%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $160.0K $170.0K $160.0K
YoY Change -5.88% 21.43% -5.88%
Total Short-Term Liabilities $18.01M $16.45M $18.01M
YoY Change 19.19% -10.11% 19.19%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $30.00K $0.00
YoY Change -100.0% -85.0% -100.0%
Other Long-Term Liabilities $268.0K $1.300M $1.060M
YoY Change -20.71% -17.72% -19.7%
Total Long-Term Liabilities $268.0K $1.330M $1.060M
YoY Change -20.71% -25.28% -28.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.01M $16.45M $18.01M
Total Long-Term Liabilities $268.0K $1.330M $1.060M
Total Liabilities $19.88M $18.56M $19.88M
YoY Change 14.72% -10.81% 14.71%
SHAREHOLDERS EQUITY
Retained Earnings -$178.3M
YoY Change 9.43%
Common Stock $201.3M
YoY Change 6.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $22.07M $26.06M $22.07M
YoY Change
Total Liabilities & Shareholders Equity $41.94M $44.62M $41.94M
YoY Change -0.73% -5.36% -0.73%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2016
OPERATING ACTIVITIES
Net Income -$4.430M -$3.146M -$15.37M
YoY Change 80.08% -41.12% -24.2%
Depreciation, Depletion And Amortization $270.0K $290.0K $1.048M
YoY Change -6.9% 15.54% 19.09%
Cash From Operating Activities -$3.150M -$1.170M -$10.60M
YoY Change 11.7% -70.08% -40.37%
INVESTING ACTIVITIES
Capital Expenditures -$350.0K -$560.0K $1.414M
YoY Change -36.36% -31.71% -21.58%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$350.0K -$560.0K -$1.414M
YoY Change -36.36% -30.0% -20.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $9.500M $9.520M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -50.00K 9.490M 9.350M
YoY Change -44.44% -47550.0% -8600.0%
NET CHANGE
Cash From Operating Activities -3.150M -1.170M -10.60M
Cash From Investing Activities -350.0K -560.0K -1.414M
Cash From Financing Activities -50.00K 9.490M 9.350M
Net Change In Cash -3.550M 7.760M -2.724M
YoY Change 2.6% -264.06% -86.14%
FREE CASH FLOW
Cash From Operating Activities -$3.150M -$1.170M -$10.60M
Capital Expenditures -$350.0K -$560.0K $1.414M
Free Cash Flow -$2.800M -$610.0K -$12.01M
YoY Change 23.35% -80.26% -38.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
747000
CY2015Q4 us-gaap Assets
Assets
42251000
CY2015Q4 us-gaap Goodwill
Goodwill
2926000
CY2016 dei Document Type
DocumentType
10-K
CY2016Q4 us-gaap Inventory Net
InventoryNet
13523000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
251000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
9784000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1505000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
33987000
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2016 dei Trading Symbol
TradingSymbol
BIOL
CY2016 dei Entity Registrant Name
EntityRegistrantName
BIOLASE, INC
CY2016 dei Entity Central Index Key
EntityCentralIndexKey
0000811240
CY2016 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
843000
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
338000
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
67570951
CY2016Q2 dei Entity Public Float
EntityPublicFloat
38006498
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11699000
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
200000
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8948000
CY2015Q4 us-gaap Inventory Net
InventoryNet
12566000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1387000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
34800000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4478000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3727000
CY2015Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
51000
CY2015Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
738000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
23000
CY2015Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
159000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
68000
CY2016Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
773000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
268000
CY2016Q4 us-gaap Liabilities
Liabilities
19876000
CY2015Q4 us-gaap Liabilities
Liabilities
17326000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
58000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
201198000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
188622000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-876000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-801000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-178325000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-162954000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
22065000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41941000
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1209000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
88494
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
67565951
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
67565951
CY2015 biol Excise Tax
ExciseTax
361000
CY2015 biol Litigation Expense Recovered
LitigationExpenseRecovered
731000
CY2015 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20278000
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-185000
CY2014 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18926000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20100000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18814000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
178000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
112000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-20278000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-18926000
CY2015 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-244000
CY2014 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-283000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20522000
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19209000
CY2016 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
2184000
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-826000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
52000
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1989000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-79000
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17555000
CY2016 biol Convertible Preferred Stock And Warrants Issuance Cost
ConvertiblePreferredStockAndWarrantsIssuanceCost
480000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
880000
CY2014 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1295000
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
696000
CY2015 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-6000
CY2014 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-9000
CY2015 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
86000
CY2015 us-gaap Inventory Write Down
InventoryWriteDown
647000
CY2014 us-gaap Inventory Write Down
InventoryWriteDown
585000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
3350000
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
60000
CY2016 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
70000
CY2016 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
51000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
644000
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
705000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
65000
CY2016 us-gaap Increase Decrease In Customer Deposits
IncreaseDecreaseInCustomerDeposits
16000
CY2015 us-gaap Increase Decrease In Customer Deposits
IncreaseDecreaseInCustomerDeposits
-27000
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3322000
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-640000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-264000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
803000
CY2015 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-259000
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-873000
CY2014 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-415000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-19915000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-17941000
CY2015 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
74000
CY2014 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-458000
CY2015Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1345000
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42232000
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42232000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
8481000
CY2013Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
1964000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
310000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1233000
CY2014 us-gaap Treasury Stock Shares Retired
TreasuryStockSharesRetired
1964000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
123000
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
51118000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
42056000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
44000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3350000
CY2015 biol Common Stock Issuance Cost
CommonStockIssuanceCost
3000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3065000
CY2016 us-gaap Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
9520000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1048000
CY2016 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
2000
CY2016 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-118000
CY2016 us-gaap Inventory Write Down
InventoryWriteDown
272000
CY2015 biol Provision For Sales Returns Allowance
ProvisionForSalesReturnsAllowance
100000
CY2014 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
200000
CY2014 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
128000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
3065000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
1233000
CY2014 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-123000
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
61000
CY2014 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
60000
CY2015 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
74000
CY2015 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
200000
CY2014 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1715000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
21000
CY2014 us-gaap Increase Decrease In Customer Deposits
IncreaseDecreaseInCustomerDeposits
-174000
CY2014 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
451000
CY2015 biol Increase Decrease In Accrued Legal Settlement
IncreaseDecreaseInAccruedLegalSettlement
1664000
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-971000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10647000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-17772000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-16201000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
198000
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
25000
CY2014 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1778000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-197000
CY2015 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
107000
CY2014 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
16875000
CY2014 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
21508000
CY2014 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
45000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9520000
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
51118000
CY2015 biol Deposit On Capital Lease
DepositOnCapitalLease
42000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
44000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
312000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
46752000
CY2014 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-234000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
30120000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1440000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1414000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1803000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1414000
CY2016 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
171000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
9350000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-105000
CY2016 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-64000
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-206000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2775000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-19861000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31560000
CY2016 us-gaap Interest Paid
InterestPaid
4000
CY2015 us-gaap Interest Paid
InterestPaid
4000
CY2016 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
76000
CY2015 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
57000
CY2014 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
52000
CY2015 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
378000
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
251000
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1137000
CY2014 us-gaap Interest Paid
InterestPaid
148000
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of these consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) requires the Company to make estimates and assumptions that affect amounts reported in the consolidated financial statements and the accompanying notes. Significant estimates in these consolidated financial statements include allowances on accounts receivable, inventory, and deferred taxes, as well as estimates for accrued warranty expenses, goodwill and the ability of goodwill to be realized, revenue deferrals, effects of stock-based compensation and warrants, contingent liabilities, and the provision or benefit for income taxes. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may differ materially from those estimates. </p></div>
CY2016 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk, Interest Rate Risk and Foreign Currency Exchange Rate </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Financial instruments which potentially expose the Company to a concentration of credit risk consist principally of cash and cash equivalents, restricted cash, and trade accounts receivable. The Company maintains its cash and cash equivalents and restricted cash with established commercial banks. At times, balances may exceed federally insured limits. To minimize the risk associated with trade accounts receivable, management performs ongoing credit evaluations of customers&#8217; financial condition and maintains relationships with the Company&#8217;s customers that allow management to monitor current changes in business operations so the Company can respond as needed. The Company does not, generally, require customers to provide collateral before it sells them its products. However, the Company has required certain distributors to make prepayments for significant purchases of products. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of the Company&#8217;s revenue is denominated in U.S.&#160;dollars, including sales to international distributors. Only a small portion of its revenue and expenses is denominated in foreign currencies, principally the Euro and Indian Rupee. The Company&#8217;s foreign currency expenditures primarily consist of the cost of maintaining offices, consulting services, and employee-related costs. During the years ended December 31, 2016, 2015, and 2014 the Company did not enter into any hedging contracts. Future fluctuations in the value of the U.S.&#160;dollar may affect the price competitiveness of the Company&#8217;s products outside the U.S.&nbsp;&nbsp;</p></div>
CY2016Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9500000
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4800000
CY2014Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11500000
CY2014Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
34800000
CY2016Q4 biol Working Capital
WorkingCapital
16000000
CY2016Q4 biol Cash And Cash Equivalents And Restricted Cash
CashAndCashEquivalentsAndRestrictedCash
9200000
CY2016 us-gaap Depreciation
Depreciation
997000
CY2015 us-gaap Depreciation
Depreciation
817000
CY2014 us-gaap Depreciation
Depreciation
627000
CY2016 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2016Q4 biol Undelivered Elements Training Installation And Product And Support Services
UndeliveredElementsTrainingInstallationAndProductAndSupportServices
1404000
CY2015Q4 biol Undelivered Elements Training Installation And Product And Support Services
UndeliveredElementsTrainingInstallationAndProductAndSupportServices
1608000
CY2016 us-gaap Sales Returns And Allowances Goods
SalesReturnsAndAllowancesGoods
210000
CY2015 us-gaap Sales Returns And Allowances Goods
SalesReturnsAndAllowancesGoods
210000
CY2016Q4 us-gaap Extended Product Warranty Accrual
ExtendedProductWarrantyAccrual
1500000
CY2015Q4 us-gaap Extended Product Warranty Accrual
ExtendedProductWarrantyAccrual
1400000
CY2016Q4 biol Percentage Of Fair Value Of Exchange To Recognize Revenue
PercentageOfFairValueOfExchangeToRecognizeRevenue
0.25
CY2016Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
933000
CY2016 us-gaap Advertising Expense
AdvertisingExpense
351000
CY2015 us-gaap Advertising Expense
AdvertisingExpense
929000
CY2014 us-gaap Advertising Expense
AdvertisingExpense
543000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3065000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3350000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1233000
CY2016Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4000000
CY2015Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4400000
CY2016 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20537000
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17371000
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13606000
CY2016Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
9699000
CY2015Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
8850000
CY2016Q4 biol Royalty Revenues Receivable
RoyaltyRevenuesReceivable
62000
CY2015Q4 biol Royalty Revenues Receivable
RoyaltyRevenuesReceivable
61000
CY2016Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
23000
CY2015Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
37000
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1200000
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1800000
CY2016Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
4837000
CY2015Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3627000
CY2016Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
2261000
CY2015Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1379000
CY2016Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6425000
CY2015Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7560000
CY2016Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
1700000
CY2015Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2100000
CY2016Q4 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
10551000
CY2015Q4 biol Property Plant And Equipment Gross Excluding Land
PropertyPlantAndEquipmentGrossExcludingLand
9883000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6225000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6314000
CY2016Q4 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
4326000
CY2015Q4 biol Property Plant And Equipment Net Excluding Land
PropertyPlantAndEquipmentNetExcludingLand
3569000
CY2016Q4 us-gaap Land
Land
152000
CY2015Q4 us-gaap Land
Land
158000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2147000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2303000
CY2016Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
638000
CY2015Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
445000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
782000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
681000
CY2016Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
159000
CY2015Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
167000
CY2016Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
906000
CY2015Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
467000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
213000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
498000
CY2016Q4 us-gaap Extended Product Warranty Accrual Current
ExtendedProductWarrantyAccrualCurrent
1487000
CY2015Q4 us-gaap Extended Product Warranty Accrual Current
ExtendedProductWarrantyAccrualCurrent
1428000
CY2016Q4 biol Deferred Royalties Current
DeferredRoyaltiesCurrent
142000
CY2015Q4 biol Deferred Royalties Current
DeferredRoyaltiesCurrent
261000
CY2016Q4 us-gaap Deferred Revenue
DeferredRevenue
3033000
CY2015Q4 us-gaap Deferred Revenue
DeferredRevenue
3297000
CY2016Q4 biol Deferred Royalties Noncurrent
DeferredRoyaltiesNoncurrent
23000
CY2015Q4 biol Deferred Royalties Noncurrent
DeferredRoyaltiesNoncurrent
142000
CY2016 us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
18000
CY2015 us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
119000
CY2016 us-gaap Litigation Settlement Amount
LitigationSettlementAmount
1400000
CY2016Q4 biol Legal Settlement At Present Value
LegalSettlementAtPresentValue
1200000
CY2016 biol Settlement Expense For Dismissal Of Patent Infringement Lawsuit Recovered
SettlementExpenseForDismissalOfPatentInfringementLawsuitRecovered
68000
CY2016 us-gaap Royalty Revenue
RoyaltyRevenue
119000
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.034
CY2016 biol Indefinite Lived Intangible Assets Useful Life
IndefiniteLivedIntangibleAssetsUsefulLife
Indefinite life
CY2016Q4 us-gaap Goodwill Gross
GoodwillGross
2926000
CY2015 us-gaap Royalty Revenue
RoyaltyRevenue
119000
CY2016Q4 biol Deferred Royalties
DeferredRoyalties
142000
CY2015Q4 biol Deferred Royalties
DeferredRoyalties
261000
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.005
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.002
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.011
CY2016Q4 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
0
CY2016 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
51000
CY2015 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
63000
CY2014 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
69000
CY2016Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2800000
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2800000
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
22000
CY2015 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
30000
CY2014 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
27000
CY2016 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
69000
CY2015 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
87000
CY2014 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
25000
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
91000
CY2015 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
117000
CY2014 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
52000
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
60000
CY2015 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
61000
CY2014 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
60000
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.404
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.402
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.374
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.030
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.031
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.033
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.031
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.019
CY2016 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.002
CY2015 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.001
CY2014 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.001
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.006
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.004
CY2014 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.010
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.009
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.023
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.005
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.008
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.009
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.006
CY2016Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
47000
CY2015Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
104000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
2117000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves
2527000
CY2016Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
8000
CY2015Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
8000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4966000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4072000
CY2016Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
9000
CY2015Q4 us-gaap Deferred Tax Assets State Taxes
DeferredTaxAssetsStateTaxes
9000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
2379000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
2471000
CY2016Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
940000
CY2015Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
905000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
656000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
219000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000
CY2016Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
201000
CY2015Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
345000
CY2016Q4 us-gaap Deferred Tax Assets Other Comprehensive Loss
DeferredTaxAssetsOtherComprehensiveLoss
252000
CY2015Q4 us-gaap Deferred Tax Assets Other Comprehensive Loss
DeferredTaxAssetsOtherComprehensiveLoss
320000
CY2016Q4 us-gaap Deferred Tax Assets Unrealized Currency Losses
DeferredTaxAssetsUnrealizedCurrencyLosses
136000
CY2015Q4 us-gaap Deferred Tax Assets Unrealized Currency Losses
DeferredTaxAssetsUnrealizedCurrencyLosses
136000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
43687000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
38753000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
54742000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
49650000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
54310000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
49514000
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
432000
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
136000
CY2016Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
876000
CY2015Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
813000
CY2016Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
354000
CY2015Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
61000
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1230000
CY2015Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
874000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
124000000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
75200000
CY2016 biol Unrecognized Tax Benefits That Would Impact Additional Paid In Capital
UnrecognizedTaxBenefitsThatWouldImpactAdditionalPaidInCapital
7100000
CY2015 biol Unrecognized Tax Benefits That Would Impact Additional Paid In Capital
UnrecognizedTaxBenefitsThatWouldImpactAdditionalPaidInCapital
6900000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
568000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2016 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
568000
CY2015Q4 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
0
CY2016Q4 biol Lease Facility Area
LeaseFacilityArea
57000
CY2015Q1 biol Period For Extended Lease
PeriodForExtendedLease
2020-04-30
CY2015Q1 biol Provisions For Tenant Improvement Allowance Maximum
ProvisionsForTenantImprovementAllowanceMaximum
398000
CY2015Q1 biol Capital Lease Agreement Lease Term
CapitalLeaseAgreementLeaseTerm
P30M
CY2016 us-gaap Fair Value Inputs Discount Rate
FairValueInputsDiscountRate
0.016
CY2016Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
159000
CY2016Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
0
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
932000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
734000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2541000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1000000
CY2016Q4 us-gaap Unrecorded Unconditional Purchase Obligation Balance Sheet Amount
UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
18000000
CY2016Q4 biol Litigation Settlement Amount Receivable Non Current
LitigationSettlementAmountReceivableNonCurrent
825000
CY2016Q4 biol Receivable For Legal Settlements On First Anniversary
ReceivableForLegalSettlementsOnFirstAnniversary
275000
CY2016Q4 biol Receivable For Legal Settlements On Second Anniversary
ReceivableForLegalSettlementsOnSecondAnniversary
275000
CY2016Q4 biol Receivable For Legal Settlements On Third Anniversary
ReceivableForLegalSettlementsOnThirdAnniversary
275000
CY2016Q4 biol Litigation Settlement Amount Receivable Current
LitigationSettlementAmountReceivableCurrent
550000
CY2016 us-gaap Loss Contingency Settlement Agreement Terms
LossContingencySettlementAgreementTerms
As part of the settlement, Fotona agreed to pay the Company a total of $1.4 million, with $550,000 payable within 10 days of March 24, 2015 and the remaining, $825,000 payable in three increments of $275,000 each to be paid no later than the first, second, and third anniversary of the effective date of the agreement.
CY2016 biol Dividend Declared
DividendDeclared
0
CY2015 biol Dividend Declared
DividendDeclared
0
CY2014 us-gaap Dividends Payable Date Declared Day Month And Year
DividendsPayableDateDeclaredDayMonthAndYear
2014-03-05
CY2014 us-gaap Dividends Payable Date Of Record Day Month And Year
DividendsPayableDateOfRecordDayMonthAndYear
2014-03-14
CY2014 us-gaap Dividend Payable Date To Be Paid Day Month And Year
DividendPayableDateToBePaidDayMonthAndYear
2014-03-28
CY2014Q4 biol Dividends Paid Amount Per Share
DividendsPaidAmountPerShare
0.0050
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37422753
CY2014 us-gaap Dividends
Dividends
193032
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
52000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
108000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.03
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.54
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.61
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1728000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2268000
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1208000
CY2016Q2 biol Number Of Vice Presidents
NumberOfVicePresidents
2
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1295000

Files In Submission

Name View Source Status
0001564590-17-003972-index-headers.html Edgar Link pending
0001564590-17-003972-index.html Edgar Link pending
0001564590-17-003972.txt Edgar Link pending
0001564590-17-003972-xbrl.zip Edgar Link pending
biol-10k_20161231.htm Edgar Link pending
biol-20161231.xml Edgar Link completed
biol-20161231.xsd Edgar Link pending
biol-20161231_cal.xml Edgar Link unprocessable
biol-20161231_def.xml Edgar Link unprocessable
biol-20161231_lab.xml Edgar Link unprocessable
biol-20161231_pre.xml Edgar Link unprocessable
biol-ex1018_619.htm Edgar Link pending
biol-ex1019_621.htm Edgar Link pending
biol-ex1020_620.htm Edgar Link pending
biol-ex1021_618.htm Edgar Link pending
biol-ex211_345.htm Edgar Link pending
biol-ex231_344.htm Edgar Link pending
biol-ex311_8.htm Edgar Link pending
biol-ex321_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending